A Life-Saving Discovery of a Rare Tumor Led to a Life-Changing Afib Treatment
July 21, 2026
MASON, Ohio --July 21, 2026-- What began as routine care for atrial fibrillation became an opportunity for a more lasting solution. After 14 years of living with Afib, Gloria Lawless arrived for a cardioversion treatment, but an additional scan revealed a rare tumor hidden in her heart. This...
AtriCure Recognized as a Minnesota Top Workplaces for 6th Consecutive Year
June 22, 2026
MASON, Ohio --June 22, 2026-- Earning this recognition for six years underscores the consistency of AtriCure’s culture and the shared purpose of its teams. AtriCure supports its teams through a mission-driven culture focused on innovation, patient impact, and continuous improvement, alongside...
AtriCure Recognized as a Top Workplace for 11th Year
May 26, 2026
MASON, Ohio --May 26, 2026-- The recognition reflects AtriCure’s ongoing commitment to creating an environment where employees can do meaningful work, grow professionally, and contribute to improving patient outcomes. “It’s an honor to be recognized for this award, particularly because it is...
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
December 11, 2025
New technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure’s EnCompass ® clamp to reduce treatment time for surgical ablation patients MASON, Ohio --Dec. 11, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical...
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
October 28, 2025
Trial will evaluate the safety and effectiveness of the AtriCure Isolator ® Synergy™ EnCompass ® clamp and AtriClip ® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset atrial fibrillation in cardiac surgery patients MASON, Ohio --Oct....
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
September 09, 2025
New device expands AtriCure’s market opportunity in post-operative pain management while addressing a significant unmet clinical need MASON, Ohio --Sep. 9, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation...
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
July 15, 2025
Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery patients globally without a preoperative Afib diagnosis MASON, Ohio --(BUSINESS WIRE)--Jul....
AtriCure Announces First Use of the AtriClip PRO-Mini® Device
April 10, 2025
MASON, Ohio --(BUSINESS WIRE)--Apr. 10, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ®...
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
October 15, 2024
MASON, Ohio --(BUSINESS WIRE)--Oct. 15, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE...
AtriCure Receives CE-Mark for the EnCompass® Clamp
October 01, 2024
Approval provides new catalyst for AtriCure’s international growth MASON, Ohio --(BUSINESS WIRE)--Oct. 1, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain...